We examined whether antitumor immunity could be generated by the inoculation of cytokine-producing murine neuroblastoma cells (C1300), and whether the immunity might be effective for the established tumors of wild-type (wt) cells. For that purpose, we transduced low immunogenic C1300 cells with interleukin-2 (IL-2), GM-CSF, or IL-4 genes. A loss of tumorigenicity in syngeneic mice was observed using IL-2-and GM-CSF-but not IL-4-producing C1300 cells, although their in vitro growth rates were not affected by the transduction. The syngeneic mice that had rejected IL-2 or GM-CSF producers did not develop tumors of wt cells inoculated subsequently, but formed tumors of irrelevant syngeneic mammary tumor cells. Accordingly, the inoculation of IL-2 or GM-CSF producers into immunocompetent mice generated tumor-specific acquired immunity. The induced immunity using IL-2 or GM-CSF producers was also effective in eradicating established subcutaneous tumors of wt cells and in reducing the number of preexisting metastatic foci in the liver. These data suggest a potential application of IL-2-or GM-CSF-producing syngeneic tumor cells for the treatment of low immunogenic neuroblastomas.
I
nduction of effective antitumor immunity in tumorbearing hosts is often difficult, and host animals are generally tolerant of the inoculated tumors. The mechanism of this induced tolerance is not fully understood, but experimental studies suggest that several factors are involved in the phenomenon. 1 Lack of lymphocyte stimulation due to suppressive cytokines is one of the mechanisms, and defective signaling in T cells was, in fact, shown in tumor-bearing animals. [2] [3] [4] [5] As a result, tumors escape from host immune surveillance systems and grow steadily in the animals.
A neuroblastoma originates from a neural crest lineage and is a common tumor in childhood. The prognosis has not been greatly improved despite multimodal treatments. 6 In the case of patients that are Ͼ1 year old, the tumors are generally refractory to conventional radiotherapy and chemotherapy. However, several data suggested that an antitumor response was occasionally induced in patients and that spontaneous remission was observed even in advanced cases. 7 Those findings prompt us to consider that an immune therapy can be applicable to neuroblastoma patients. The expression of cytokine gene(s) in tumor cells is one possible strategy to induce an antitumor response. Among the various cytokines tested previously for their ability to induce antitumor immunity, interleukin-2 (IL-2)-mediated reactions have been investigated extensively, 8 -10 because IL-2 is required for the proliferation of cytotoxic T cells and for the activation of natural killer (NK) cells. 11, 12 The expression of the GM-CSF gene in tumor cells has also been shown to induce systemic immunity in the inoculated hosts when irradiated GM-CSF-producing tumor cells were used as a vaccine. 13, 14 Although secreted GM-CSF may not directly induce cytotoxic T cells or NK cells, vaccinations with GM-CSFsecreting tumor cells are able to induce a T-cell-mediated immune response. In contrast, IL-4 tends to inhibit the function of T helper type 1 (Th1) cells, which play major roles in cell-mediated immunity. 15 However, several studies suggest that the production of IL-4 from tumor cells could successfully induce an antitumor response. 16, 17 In a previous study, we showed that IL-2-or GM-CSFproducing murine neuroblastoma cells (C1300) could not form subcutaneous (s.c.) tumors in the syngeneic mice inoculated. 18 In this study, we further characterized the immunity induced by the inoculation of IL-2 or GM-CSF producers and showed that the immunity was also effective in diminishing established s.c. tumors and metastatic foci in the liver.
MATERIALS AND METHODS

Cells and animals
A/J and BALB/c nu/nu nude mice (6-to 7-week-old females) were purchased from the Sizuoka Laboratory Animal Center (Hamamatsu, Japan). Murine neuroblastoma C1300 cells and mammary carcinoma SY8220 cells were obtained from the Japanese Cancer Research Resources Bank (Osaka, Japan) and from Dr. Ootsu (Takeda Chemical Industries, Osaka, Japan), respectively. Both ecotropic 2 cells and amphotropic PA317 cells were secured from the American Type Culture Collection (Manassas, Va). These cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. 22 cDNAs were kindly provided by Dr. T. Yokota (Tokyo University). The establishment of respective virus producers and cytokine-producing C1300 cells has been described previously. 18 Briefly, each plasmid vector DNA harboring a cytokine cDNA was transfected into PA317 cells. After selection with G418 (Life Technologies, Gaithersburg, Md), the culture supernatants of G418-resistant PA317 cells were used to transduce ecotropic 2 cells in the presence of 8 g/mL polybrene (Aldrich Chemical Company, Milwaukee, Wis). G418-resistant 2 cells were cloned after transduction, and the culture supernatants of the respective virus-producing clones were used to transduce C1300 cells. The G418-resistant, cytokine-producing C1300 cells were cloned, and the amounts of cytokines secreted into the culture supernatants were determined with an enzyme-linked immunosorbent assay (Endogen, Cambridge, Mass).
Establishment of virus-producing cells and retrovirusmediated gene transfer
Animal studies
Wild-type (wt) or transduced cells (2 ϫ 10 6 ) were s.c. injected into syngeneic A/J or BALB/c nude mice. Tumor growth was represented either by tumor volumes based on the formula: volume ϭ /6 ϫ A ϫ B 2 , where A and B are the longest and shortest diameters, respectively, or by average tumor diameters ([A ϩ B]/2). Mice that rejected transduced cells were s.c. challenged with wt, SY8220, or C1300 cells (2 ϫ 10 6 ) transduced with vector DNA. For the treatment of established tumors, A/J mice were s.c. inoculated with wt cells (2 ϫ 10 6 ) in the left flank; after 10 days, the tumor-bearing mice were s.c. inoculated with cytokine producers in the right flank. In the liver metastasis experiment, A/J mice were intravenously injected from the tail vein with wt cells (5 ϫ 10 5 ); after 3 days, the mice were s.c. inoculated with cytokine-producer cells (2 ϫ 10 6 ). The number of metastatic foci and the ratio of liver weight to whole-body weight were examined on day 21. In this metastasis experiment, the metastatic foci found in organs other than the liver and bone marrow were rare, and the mice died of multiple liver metastases approximately on day 25. 23 Statistical analysis was performed by a one-way analysis of variance (ANOVA) or by a log rank test based on the Kaplan-Meier test.
Flow cytometry
Cells were reacted with monoclonal anti-H-2 antibody (Chemicon International, Temecula, Calif) followed by fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin antibody. As a control, cells were incubated with an isotypematched control antibody. The stained cells were analyzed by FACScan (Becton Dickinson, Mountain View, Calif) with CellQuest software (Becton Dickinson).
Histological analysis
The sections (4-or 5-m thickness) from formalin-fixed, paraffin-embedded tumors were stained with hematoxylineosin.
RESULTS
In vitro analysis
We selected each clone that secreted the highest amounts of respective cytokines (C1300/IL-2, C1300/ IL-4, and C1300/GM-CSF cells). The amounts of cytokines secreted were 2.40, 15.9, and 21.3 ng/mL per 1 ϫ 10 5 cells for 72 hours for IL-2, IL-4, and GM-CSF producers, respectively. Morphological changes were not observed posttransduction. The expression level of major histocompatibility complex class I antigens (Ags) was analyzed by flow cytometry, and the mean fluorescence values subtracted with background staining were calculated. The values of wt cells, IL-2 producers, IL-4 producers, and GM-CSF producers were 154 (arbitrary units), 127, 248, and 171, respectively. Thus, the expression of class I Ags on each clone was slightly variable. The in vitro proliferation rates of the cytokine producers were not different from that of wt cells (data not shown).
In vivo tumorigenicity
We inoculated cytokine-producing C1300 cells into syngeneic A/J mice to examine whether antitumor effects could be generated by the cytokine producers. The A/J mice injected with wt or C1300/IL-4 cells developed tumors, whereas the mice inoculated with C1300/IL-2 or C1300/GM-CSF cells did not (Fig 1) . The tumor growth of the C1300/IL-4 cells was initially retarded compared with that of wt cells but subsequently matched the size of wt tumors.
Next, we s.c. inoculated wt, C1300/IL-2, or C1300/ GM-CSF cells into immunocompromised nude mice. All of the mice developed tumors, but the tumor growth of the IL-2 or GM-CSF producers was impeded greatly compared with that of wt cells (Fig 2) . Consequently, the survival days of the mice inoculated with C1300/IL-2 and C1300/GM-CSF cells were 47.2 (average) Ϯ 1.6 (SE) and 45.6 Ϯ 0.5, respectively, and were significantly longer than those of the mice injected with wt cells (38.2 Ϯ 2.0) ( 2 ϭ 14.0, degrees of freedom (df) ϭ 2, P Ͻ .01). The survival days of the nude mice injected with wt cells were not different from those of the A/J mice injected with wt cells (39.4 Ϯ 1.5) (P Ͼ .9). It is conceivable that ␣␤ T cells are indispensable for the loss of the tumorigenicity of the IL-2 or GM-CSF producers; however, other types of cells are also involved in this antitumor effect.
We examined whether tumor-specific acquired immunity could be generated in the A/J mice that had rejected C1300/IL-2 or C1300/GM-CSF cells. The mice were challenged with wt, vector DNA-transduced C1300 cells or with irrelevant syngeneic SY8220 cells. All of the mice that had rejected C1300/IL-2 or C1300/GM-CSF cells did not develop tumors of wt or vector DNA-transduced C1300 cells, with the exception of one mouse; however, mice did develop tumors of SY8220 cells ( Table 1 ). The survival days of the mice that were challenged with SY8220 cells were not different from those of naive mice injected with SY8220 cells (P Ͼ .05).
Treatment of established tumors
We tested the possibility that the antitumor response induced by the inoculation of cytokine producers could also be effective for the treatment of established tumors. Once s.c. tumors of wt cells had formed in the left flank of A/J mice, we injected cytokine producers into the right flank of the tumor-bearing mice at 10 days after the first inoculation. An injection of IL-2 or GM-CSF producers significantly suppressed the tumor growth of wt cells compared with that seen in control mice without the injection (C1300/IL-2-injected group: P Ͻ .01; C1300/GM-CSF-injected group: P Ͻ .01 (ANOVA)) (Fig 3, A and B) . Consequently, the survival of the mice that were inoculated with IL-2 or GM-CSF producers became longer than that of control mice (C1300/IL-2: 2 ϭ 9.65, df ϭ 1, P Ͻ .01; C1300/GM-CSF: 2 ϭ 11.1, df ϭ 1, P Ͻ .01 (log rank test)). Three of eight mice in the C1300/IL-2-injected group and four of eight mice in the C1300/GM-CSF-injected group rejected wt tumors and did not develop tumors until the end of the observation period. In contrast, none of wt tumors regressed in the C1300/IL-4-injected group (Fig 3C) . Tumor growth was not significantly different from that of control mice (P Ͼ .01), and the survival of the mice was not prolonged ( 2 ϭ 0.426, df ϭ 1, P Ͼ .05). Histopathological examination of the wt tumors that were in a regressing phase due to the inoculation of GM-CSF producer cells revealed an infiltration of mononuclear cells in the tumors (Fig 4A) . Immunohistochemical analysis showed that many CD11b (Mac-1) ϩ cells and a few CD90 (Thy-1) ϩ cells migrated around the regressing tumors (data not shown). In contrast, we did not observe cell infiltration around wt tumors in mice that contralaterally received wt cells (Fig 4B) .
In a second experimental system, we examined the Tumorigenecity C1300/IL-2 wt Ͼ100, Ͼ100, Ͼ100 0/6 Ͼ100, Ͼ100, Ͼ100 C1300/IL-2 Vector Ͼ100, Ͼ100, Ͼ100 0/6 Ͼ100, Ͼ100, Ͼ100 C1300/IL-2 SY8220 36, 42, 44 6/6 44, 46, ‫ء25‬ C1300/GM-CSF wt Ͼ100, Ͼ100, Ͼ100 0/6 Ͼ100, Ͼ100, Ͼ100 C1300/GM-CSF Vector 45, Ͼ100, Ͼ100 1/6 Ͼ100, Ͼ100, Ͼ100 C1300/GM-CSF SY8220 antitumor effect of IL-2 or GM-CSF producers on growing metastasis foci in the liver. An injection of wt cells from the tail vein of A/J mice caused multiple metastatic foci in the liver, and the ratio of liver to whole-body weight increased in proportion to the number and size of the developed foci. At 3 days after the injection of wt cells, we s.c. inoculated cytokine producers or wt cells as a control (Fig 5) . The number of live metastatic foci in the mice that received C1300/IL-2 or C1300/GM-CSF cells was significantly smaller than that of the mice inoculated with wt or C1300/IL-4 cells ( Fig  5A) . Accordingly, the ratio of liver to body weight of the mice that were injected with C1300/IL-2 or C1300/GM-CSF cells was also lower than that of the wt-or C1300/IL-4-injected mice (Fig 5B) .
DISCUSSION
In this study, we showed that an inoculation of IL-2-or GM-CSF-producing C1300 cells could induce tumorspecific acquired immunity in syngeneic mice, and that this induced immunity was also effective for established s.c. and metastatic tumors. Eradication of a growing tumor by the generation of an immune response to tumor cells is an ultimate goal of cancer treatment. However, the induction of systemic immunity is sometimes difficult to achieve, partly due to the immune tolerance for tumor cells. Cytokines such as tumor growth factor ␤1 or IL-10 secreted from tumors and/or tumor-infiltrating cells can suppress an immune response to tumor cells. 2, 5 Functional defects in T cells in tumor-bearing animals cannot provoke appropriate signal transductions and render them unable to respond to tumor cells. 3, 4 During the Ag-presenting process, dendritic cells from tumor-bearing mice showed a reduced ability to induce cytotoxic T cells. 24, 25 However, expression of the IL-2 gene in tumor cells could restore the function of T cells in tumor-bearing animals 26, 27 and consequently break the tolerance induced. The secretion of IL-2 from tumor cells, which causes the shift of Th1/Th2 balance to the Th1-dominant state, favored the generation of antitumor immunity 15, 25 and induced cytotoxic responses to preexisting tumors. 28, 29 The secretion of IL-4 induces a Th2-dominant state and therefore could not generate immunity against tumor cells (Figs 1  and 3C ).
The role of GM-CSF in the induction of a T-cellmediated response is relatively uncharacterized. 13 However, dendritic cells were shown to efficiently present Ags from apoptotic cells and consequently to be able to activate cytotoxic T cells in a tumor-specific manner. 30 Most of the studies using GM-CSF producers focused on their feasible application as a tumor vaccine, 13, 14 but a loss of tumorigenicity or a growth retardation of GM-CSF-secreting tumors has not been well demonstrated. Previous studies showed that an inoculation of irradiated GM-CSF producers could be used to suppress established tumors 13, 14, 31 or distant metastases. 32, 33 However, the antitumor effects in those studies were not strong enough to eradicate tumors. Moreover, the tested animals received a larger number of GM-CSF producers than that used in the present study. 13, 14, 31, 33 The antitumor activity of IL-2 producers on established tumors was shown to be greater than that mediated by GM-CSF producers, but not sufficient to eradicate tumors. 9, 28, 34 In the present study, however, we observed a complete regression of wt tumors that had grown to a large mass (Fig 3) .
We have reported the possibility of tumor vaccination using cytokine producers to induce systemic immunity. Syngeneic mice were inoculated with IL-2-producing, GM-CSF-producing, or wt cells that had been irradiated with 15 Gy. The mice did not develop respective tumors and were subsequently challenged with wt cells. All of the mice that had received irradiated wt cells developed wt tumors that were subsequently inoculated, and the tumor growth rate remained the same as that of wt cells inoculated in naive mice. However, none of the mice injected with irradiated IL-2 or GM-CSF producers formed wt tumors. 35 Irradiation with 15 Gy abolished the proliferation capacity of C1300 cells but could maintain approximately half of the capacity to secrete respective cytokines. 35 Thus, the vaccines using cytokine producers could induce protective immunity to low immunogenic C1300 cells.
The immune response induced by the secretion of IL-2 or GM-CSF from tumor cells was mediated in part by ␣␤ T cells, because the tumorigenicity of the cytokine producers was abolished in nude mice (Fig 2) . The acquired immunity observed in this study also supported the involvement of T cells (Table 1) . However, the growth of cytokine producers in nude mice was significantly retarded compared with that of producers inoculated in syngeneic mice. This finding suggests that non-T cells are also involved in the antitumor response. Both NK cells and granulocytes plus macrophages might be included in the case of IL-2 producers 12 and GM-CSF producers, respectively. In the present immunohistochemical analysis, we observed a migration of CD11b ϩ cells around wt tumors in the mice that were treated with C1300/GM-CSF cells. Although the histological findings are affected by various factors, CD11b ϩ cells such as macrophages may play a role in the eradication of growing tumors.
Previous studies on cytokine gene therapy for neuroblastomas focused on the use of IL-2, 36 B7, 37 or interferon-␥ gene. 38 To our knowledge, the antitumor effect caused by the expression of GM-CSF in neuroblastomas has not been reported, with the exception of our previous study. 18 Because the inoculation of irradiated C1300 cells into naive syngeneic mice did not generate acquired immunity, 35 the production of IL-2 or GM-CSF from tumor cells is one of the strategies for the treatment of low immunogenic tumors. Moreover, because neuroblastoma cells originate from a neural crest, it is possible to express a gene in a neuroblastoma-specific fashion using a promoter that is preferentially used in neuroblastoma cells. 39, 40 This study provides a strategic design for the elimination of residual or metastatic neuroblastomas by the expression of cytokine gene(s) in a neuroblastoma-specific manner.
